Table 3.
Correlation analysis of LDL size with lipid profile, modified LDLs, HDL composition and Lp-PLA2 activity in patients with type 2 diabetes and control subjects
| DM2 patients | Control subjects | |||
|---|---|---|---|---|
| |
R |
P |
R |
P |
| HbA1c |
−0.160 |
0.071 |
−0.103 |
0.601 |
| Insulin |
−0.076 |
0.418 |
0.008 |
0.937 |
| Total cholesterol |
−0.185 |
0.035 |
−0.326 |
0.016 |
| Triglycerides |
−0.553 |
< 0.001 |
−0.427 |
0.001 |
| VLDLc |
−0.513 |
< 0.001 |
−0.423 |
0.001 |
| LDLc |
−0.152 |
0.083 |
−0.333 |
0.014 |
| HDLc |
0.407 |
< 0.001 |
0.096 |
0.491 |
| NEFA |
−0.226 |
0.004 |
−0.042 |
0.765 |
| apoB |
−0.246 |
0.005 |
−0.458 |
< 0.001 |
| apoA-I |
0.264 |
0.002 |
−0.033 |
0.811 |
| apoA-II |
−0.068 |
0.472 |
−0.099 |
0.476 |
| Oxidized LDL |
−0.390 |
< 0.001 |
−0.472 |
< 0.001 |
| Glycated LDL |
−0.273 |
0.003 |
−0.151 |
0.307 |
| LDL(-) |
−0.020 |
0.828 |
0.030 |
0.849 |
| Cholesterol in HDL |
0.321 |
0.002 |
0.208 |
0.244 |
| Trigycerides in HDL |
−0.398 |
< 0.001 |
−0.150 |
0.405 |
| Phospholipids in HDL |
0.437 |
< 0.001 |
0.067 |
0.712 |
| apoA-I in HDL |
−0.205 |
0.047 |
0.086 |
0.635 |
| apoA-II in HDL |
−0.169 |
0.103 |
−0.069 |
0.739 |
| NEFA in HDL |
−0.010 |
0.925 |
0.086 |
0.635 |
| PON1 |
0.016 |
0.867 |
0.024 |
0.872 |
| Total Lp-PLA2 activity |
−0.123 |
0.172 |
0.025 |
0.862 |
| HDL-Lp-PLA2 activity |
0.030 |
0.745 |
0.061 |
0.680 |
| % of HDL-Lp-PLA2 | 0.191 | 0.034 | 0.064 | 0.662 |
Bold type indicates the loss of statistical significance in the control group compared to diabetic patients.